Press release
Award-Winning Eczema App, ATOPIYO, Launches Text Posting Feature: Introducing "Tweet Piyo" - Beyond Visual Tracking to Strengthen Community Support for 31 Million Americans
Image: https://www.globalnewslines.com/uploads/2025/08/31dc6fa35aca0ded5c44141944d89a0f.jpg
Background: Meeting User Needs
Until now, ATOPIYO has been widely used for sharing and recording eczema-related photos to foster empathy and information exchange among patients. However, many users expressed a desire to also post quick notes such as "I just want to ask in words" or "I want to share my daily worries and findings without an image." The new text posting feature "Tweet Piyo" addresses this demand, making communication easier and more inclusive.
For image posts, a new function allows users to blur photos posted by others, such as severe cases, giving them control over what they view.
How It Works
Text Posting - Tap the pencil icon at the bottom of the app to write and share a text-only post.
Blur - Tap the eye icon in the lower right corner to toggle blurred or unblurred display of images.
About ATOPIYO
Image: https://www.globalnewslines.com/uploads/2025/08/cf30304e88cd2b3ce795d98bc908cd78.jpg
ATOPIYO is Japan's first anonymous image-sharing app specifically designed for eczema patients. Developed by former eczema patient Ryotaro Ako, the app enables users to anonymously record and share eczema-specific skin symptoms, itching experiences, and skincare routines to support early recovery.
Since launch, ATOPIYO has grown into Japan's largest eczema patient platform, with over 30,000 downloads and 67,000 uploaded images as of August 2025. It has won 12 national awards, including Japan's National Public Health Award. The app has also launched in the United States in June 2025.
ATOPIYO currently collaborates with 7 university hospitals and research institutions for big data analysis and pharmaceutical partnerships for disease awareness. Research utilizing ATOPIYO data was published in the prestigious international medical journal "Allergy" in May 2025, demonstrating its academic impact.
AppStore: https://apps.apple.com/app/id6475762535
GooglePlay: https://play.google.com/store/apps/details?id=com.atopiyo.atopiyous
Future Outlook
ATOPIYO will continue partnering with pharmaceutical companies and medical institutions to advance eczema research, product development, and disease awareness through digital innovation. The addition of text posting is the first of many planned feature expansions aimed at creating a more comprehensive and supportive platform for eczema patients.
"With 31 million Americans living with eczema, our mission goes beyond symptom tracking. The text posting feature reflects our commitment to meeting the evolving needs of our community." - Ryotaro Ako, Founder of ATOPIYO
Founder's Profile
Ryotaro Ako, a former eczema patient, is a programmer, holds a master's degree in engineering, and is a Certified Public Accountant. Having experienced three allergic conditions-eczema, asthma, and rhinitis-he engaged in volunteer work with patient associations. He developed ATOPIYO himself, drawing on feedback from eczema patients, insights from his wife Akiko Ako, a licensed pharmacist, and technical guidance from software engineers.
Major Awards
10th Health and Longevity Extension! Award - National Government Public Health Award
InnoVation 2020 Generation Award - National Government Innovation Award
Japan Healthcare Business Contest 2020 - National Government Excellence & Special Awards
Media Contact
Company Name: Atopiyo LLC
Contact Person: Ryotaro Ako
Email: Send Email [http://www.universalpressrelease.com/?pr=awardwinning-eczema-app-atopiyo-launches-text-posting-feature-introducing-tweet-piyo-beyond-visual-tracking-to-strengthen-community-support-for-31-million-americans]
City: Ichikawa
State: Chiba
Country: Japan
Website: https://www.atopiyo.com/en/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Award-Winning Eczema App, ATOPIYO, Launches Text Posting Feature: Introducing "Tweet Piyo" - Beyond Visual Tracking to Strengthen Community Support for 31 Million Americans here
News-ID: 4154596 • Views: …
More Releases from Getnews
The U.S. Green Card: Turning a Temporary Stay into a Permanent American Future
Image: https://www.globalnewslines.com/uploads/2025/12/1766183100.jpg
For many people, a U.S. visa is only the beginning. What they truly want is certainty - the ability to live, work, and plan their future in the United States without expiry dates, renewals, or ongoing fear that a single decision could unravel years of effort.
That certainty is called a Green Card.
Yet despite its importance, the Green Card [https://larhdellaw.com/] process is often misunderstood. Some believe it is only for…
The L-1 Visa: How Global Businesses Expand to the U.S. Without Starting From Scr …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182907.jpg
For international companies with ambitions to enter the United States, few visa options are as powerful - or as misunderstood - as the L-1 Intracompany Transfer Visa.
When used correctly, the L-1 visa allows established businesses to expand into the U.S. market, transfer trusted senior staff, and build a long-term American presence without relying on lotteries, third-party sponsors, or speculative investment routes. When used incorrectly, it becomes one of the…
The B-1/B-2 Visitor Visa: Why Careful Preparation Matters More Than Ever
Image: https://www.globalnewslines.com/uploads/2025/12/1766182346.jpg
The B-1/B-2 visitor visa [https://larhdellaw.com/]is often described as the most common U.S. visa. That description, while true, can be misleading. Its familiarity causes many applicants to underestimate how closely these visas are scrutinised - and how easily an application can be refused.
In today's immigration environment, visitor visas are assessed with a level of caution that surprises even experienced international travellers. The rules themselves have not dramatically changed, but how…
The E-2 Visa Explained: How to Invest in the U.S. Without Buying a Green Card (a …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182716.jpg
For entrepreneurs, investors, and business owners looking to live and work in the United States, the E-2 Treaty Investor Visa remains one of the most attractive - and misunderstood - visa options available.
Every year, we speak with applicants who have invested significant money, launched businesses, or even hired staff, only to discover that their E-2 application was refused or delayed due to avoidable legal and strategic errors. The truth…
More Releases for ATOPIYO
Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan I …
Atopic Dermatitis Market reached US$ 10.72 Billion in 2024 and is expected to reach US$ 31.68 Billion by 2033, growing at a CAGR of 13.7% during the forecast period 2025-2033.
Latest Japan‐Related News
Japan's top eczema app "Atopiyo" expands to the US - the app, developed in Japan, is now internationally available
Dupixent (dupilumab) receives approval in Japan for treating atopic dermatitis and other conditions
Maruho to co-develop topical biologic…
